EpCAMhigh and EpCAMlow circulating tumour cells in metastatic prostate and breast cancer patients

Sanne Mutter, Mariangela Manicone, Elisabetta Rossi, Rita Lampignano (Corresponding Author), Anne Margreet Sofie Berghuis, Kiki Carlijn Andree, Maarten Joost IJzerman, Leonardus Wendelinus Mathias Marie Terstappen (Corresponding Author)

Research output: Contribution to journalArticleAcademicpeer-review

68 Citations (Scopus)
97 Downloads (Pure)


The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) circulating tumor cells (CTC) enumerated by CellSearch® in blood of cancer patients is strongly associated with poor prognosis. This raises the question about the presence and relation with clinical outcome of low EpCAM expressing CTC (EpCAMlow CTC). In the EU-FP7 CTC-Trap program, we investigated the presence of EpCAMhigh and EpCAMlow CTC using CellSearch, followed by microfiltration of the EpCAMhigh CTC depleted blood. Blood samples of 108 castration-resistant prostate cancer patients and 22 metastatic breast cancer patients were processed at six participating sites, using protocols and tools developed in the CTC-Trap program. Of the prostate cancer patients, 53% had ≥5 EpCAMhigh CTC and 28% had ≥5 EpCAMlow CTC. For breast cancer patients, 32% had ≥5 EpCAMhigh CTC and 36% had ≥5 EpCAMlow CTC. 70% of prostate cancer patients and 64% of breast cancer patients had in total ≥5 EpCAMhigh and/or EpCAMlow CTC, increasing the number of patients in whom CTC are detected. Castration-resistant prostate cancer patients with ≥5 EpCAMhigh CTC had shorter overall survival versus those with <5 EpCAMhigh CTC (p = 0.000). However, presence of EpCAMlow CTC had no relation with overall survival. This emphasizes the importance to demonstrate the relation with clinical outcome when presence of CTC identified with different technologies are reported, as different CTC subpopulations can have different relations with clinical outcome.
Original languageEnglish
Pages (from-to)35705-35716
Number of pages12
Issue number86
Publication statusPublished - 2 Nov 2018


  • Circulating tumor cells (CTC)
  • EpCAM
  • castrate-resistant prostate cancer (CRPC)
  • metastatic breast cancer (mBC)
  • Epithelial-to-mesenchymal transition (EMT)


Dive into the research topics of 'EpCAMhigh and EpCAMlow circulating tumour cells in metastatic prostate and breast cancer patients'. Together they form a unique fingerprint.

Cite this